Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Research: Gene expression signature may increase risk of tumor recurrence or spread prostate cancer

A team led by Massachusetts General Hospital researchers has identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer.

16 Apr 2013

Correcting prostate specific antigen levels for genetic variants can have significant consequences

Genetic variants have been identified which can increase serum prostate specific antigen concentrations and prostate cancer risk. A new study published in The Journal of Urology reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others.

16 Apr 2013

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

Research on soy-based treatment for colorectal cancer presented at AACR annual meeting

Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting.

12 Apr 2013

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

12 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.

11 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Study: Benefort broccoli yields higher levels of health-promoting compound

Field trials and genetic studies have shown that a new variety of broccoli reliably yields higher levels of a health-promoting compound.

10 Apr 2013

Findings could help develop new ways to predict risks of tobacco-associated cancers

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Researchers discover new genetic link between rapid growth of healthy fetuses and cancer

Two researchers at the National Institutes of Health discovered a new genetic link between the rapid growth of healthy fetuses and the uncontrolled cell division in cancer.

9 Apr 2013

Study: Chicken-killing virus is a promising treatment for prostate cancer

A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Research: Gene expression signature may increase risk of tumor recurrence or spread prostate cancer

Correcting prostate specific antigen levels for genetic variants can have significant consequences

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Research on soy-based treatment for colorectal cancer presented at AACR annual meeting

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Study: microRNA is designed to stop proliferation of prostate cancer cells

Study: Benefort broccoli yields higher levels of health-promoting compound

Findings could help develop new ways to predict risks of tobacco-associated cancers

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BRCA2 gene mutation carriers at greater risk for more advanced prostate cancer

New immunotherapies are seldom developed for childhood cancer

Researchers discover new genetic link between rapid growth of healthy fetuses and cancer

Study: Chicken-killing virus is a promising treatment for prostate cancer

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

American Cancer Society announces new research, training grants for fiscal year 2013

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in